Focused radiation for brain metastases that have bled
Tests focused radiation therapy for bleeding brain metastases in adults.
Key facts
- Who runs it
- Centre Francois Baclesse
- Where
- France4 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 46 people, planned
- Started
- 16 Jan 2019
- Expected to end
- Jan 2028
- Type of study
- Interventional
- Treatments tested
- FSRT Stereotactic radiation therapy
- Record updated
- 11 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with fewer than 4 brain metastases from a solid tumor, with signs of recent bleeding inside at least one of them. It tests stereotactic radiotherapy (FSRT), a precisely targeted radiation.
- Age
- Over 18 years
- Sex
- All sexes
- Disease stage
- Fewer than 4 brain metastases of a solid tumor (melanoma included), proven by tissue test. Lesions 5 to 30 mm across. At least one shows bleeding signs on CT or MRI. Performance Status 0 or 1. Life expectancy over 6 months. No tumor spread to the brain lining and no brainstem metastasis. A specialist team must approve stereotactic radiotherapy. People who had a metastasis removed and have 1 to 3 brain lesions can join.
- Earlier treatment
- No prior stereotactic radiation to the brain and no prior whole-brain radiation. Chemotherapy, hormone therapy, anti-angiogenic and other cancer drugs must stop at least 7 days before FSRT. They can restart 7 days after radiotherapy ends. Immunotherapy does not have to stop.
- Biomarker or test result
- DS-GPA score by tumor type: lung adenocarcinoma 2 or more; other lung 2.5 or more; kidney 2.5 or more; breast 2.5 or more; digestive cancer 3 or more; melanoma 1.5 or more. Platelets at least 100,000 cells / mm3.
Main reasons for not taking part
- Small cell lung cancer, germ cell tumors, lymphoma, leukemia or multiple myeloma
- Blood thinners or anti-platelet drugs during FSRT, unless they can stop 5 days before and restart 2 weeks after
- Cannot have brain MRI or gadolinium contrast
- Bleeding disorders other than bleeding inside the brain tumor
- Neurodegenerative disease, or a disease making tissue more sensitive to radiation (such as neurofibromatosis)
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Age> 18 years
- Performance Status 0 or 1
- Patient with less than 4 brain metastases [of a solid tumor, including melanoma, with a histologically proven diagnosis for the solid tumor; Patients who have had a metastasectomy and 1 to 3 brain metastatic lesions are eligible
- Brain injury (s) measuring between 5 and 30 mm in diameter
- Patient eligible for stereotactic radiotherapy after a decision of the multidisciplinary committee
- Presence of intra-tumor bleeding signals on at least one brain injury before stereotactic irradiation and defined by :; hyperdense lesion on the non-injected CT (treatment scanner) and / or,; spontaneously hyperintense lesion on T1 MRI sequences without gadolinium injection and / or,; lesion with hypo signal on T2 sequences *
- Absence of meningeal tumor invasion
- Absence of brainstem metastasis
- DS-GPA depending on the histological type (https://brainmetgpa.com/#start):; Lung Adecarcinoma: DS-GPA 2 or +; Non-adenocarcinoma lung: DS-GPA 2.5 or +; Kidney: DS-GPA 2.5 or +; Breast: DS-GPA 2.5 or +; Digestive cancer: DS-GPA 3 or +; Melanoma: DS-GPA 1.5 or +
- Patient without concomitant anti-cancer therapy (chemotherapy, hormone therapy, anti-angiogenic or other anti-cancer treatments). Treatments should be suspended for at least 7 days before the start of FSRT radiotherapy. The treatment can be resumed 7 days after the end of radiotherapy. It's not mandatory to suspend immunotherapy
- Life expectancy estimated at over 6 months
- Patient cooperating sufficiently to perform the treatment with the use of a thermoformed mask
- Patient whose neuropsychological capacities make it possible to follow the requirements of the protocol
- Patient affiliated to a social security scheme
- Patient giving written consent
Who cannot take part
- Patient with a concomitant neurodegenerative disease
- Any symptoms not attributable to cerebral metastasis or cancerous pathology and requiring long-term use of corticosteroids (regardless of dose)
- Planning of the treatment on the target metastasis delivering a dose> 5 Gy on other metastases concomitant
- Patient with prior cerebral stereotactic irradiation
- Patient with small cell lung cancer, germ cell tumors, lymphoma, leukemia and multiple myeloma
- Hemorrhagic disorders other than intra-tumor bleeding from brain lesion (s)
- Radiosensitizing systemic disease (Neurofibromatosis ...)
- History of total brain irradiation
- Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study
- Anticoagulant treatment, and / or anti-platelet aggregation with curative et prophylaxic dose during FSRT. If treatment can be delayed for at least 5 days before starting FSRT and resumed 2 weeks after completion of FSRT, the patient is eligible
- Contraindication to brain MRI or gadolinium injection
- Thrombocytopenia less than 100,000 cells / mm3
- Hemorrhagic metastasis (s) of the brainstem
- Participation in a therapeutic trial that could compromise the conduct of study
- Patient deprived of liberty or under guardianship
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
The group in the trial
- FSRT Stereotactic radiation therapyTreatment being tested
Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal: Phase 2 Study in 2 Steps
- Plain-language title
- Focused radiation for brain metastases that have bledGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Publications
- Record updated
- 11 February 2025